Switzerland's DocMorris Q2 external revenue rises on Rx customer growth, digital services expansion

DocMorris AG

15/07/2026 06:13

Overview
Switzerland online pharmacy's preliminary Q2 external revenue rose 15% yr/yr
Germany Rx revenue grew 46% in Q2; Digital Services up 80%
Adjusted EBITDA expected to improve further in Q2 vs Q1

Outlook
DocMorris will update 2026 guidance as part of half-year results on 19 August

Result Drivers
PRESCRIPTION MEDICINE GROWTH - Rx revenue rose 46% in Q2, driven by a significant increase in new Rx customers, according to CEO Walter Hess
DIGITAL SERVICES EXPANSION - Digital Services revenue grew 80% in Q2, supported by TeleClinic, retail media and marketplace, per company statement
MARKETING EFFICIENCY - Company said focus on operational and marketing efficiency supported profitability improvements, per CFO Daniel Wüest

Company press release: ID:nEQ54RGcCa

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 External Revenue
 
CHF 627.80 mln
 

Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy", 3 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the drug retailers peer group is "buy."
Wall Street's median 12-month price target for DocMorris AG is CHF8.75, about 13.9% below its July 14 closing price of CHF10.16

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)